Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 3, Issue 4, 2002, Pages 265-270

  Vokes, Everett E ^a   Charoentum, Chaiyut ^a   Gordon, Gary S ^a   Rudin, Charles M ^a   Krauss, Stuart A ^a   Hoffman, Philip C ^a   Mauer, Ann M ^a   Lee, Susie ^a   Watson, Sylvia ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Alternating chemotherapy; Cisplatin; Docetaxel; Dose dense chemotherapy; Gemcitabine; Vinorelbine

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LORAZEPAM; NAVELBINE; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0036308914     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.n.011     Document Type: Article

References (39)

1. Cancer statistics, 2001
2. Non-small cell lung cancer
3. Lung cancer
4. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
5. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
6. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Group trial
7. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
8. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
9. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
10. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
11. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
12. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial
13. Phase II trials of Taxotere in patients with non-small-cell lung cancer
14. Phase II study of docetaxel (Taxotere®) in first- and second-line NSCLC
15. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
16. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial
17. Randomized phase III trial of docetaxel versus vinotelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Study Group
18. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
19. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial
20. Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carbonplatin-paclitaxel (C-P)
21. Phase II randomized multicenter trial of two dose schedules of gemcitabine as second-line therapy in patients with advanced non-small cell lung cancer (ANSCLC)
22. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer
23. Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC)
24. Results of a phase II study of gemcitabine (GEM) as second line therapy in advanced non small cell lung cancer (NSCLC)
25. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial
26. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
27. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: Early results of a randomized trial
28. The Norton-Simon hypothesis revisited
29. Reporting results of cancer treatment
30. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
31. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer
32. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor
33. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma
34. In vivo hematopoieic progenitor expansion with G-CSF (primer) pre high-dose-therapy (HDT) accelerates neutrophil recovery
35. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
36. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer
37. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. American Society of Clinical Oncology
38. Prolonged survival in pathologic stage IIIB non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy followed by consolidation docetaxel: A phase II study (S9504) of the Southwest Oncology Group (SWOG)
39. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D)